Stage IV Salivary Gland Cancer Terminated Phase 1 Trials for Cetuximab (DB00002)

Also known as: Salivary gland cancer stage IV / Metastatic salivary gland cancer / Malignant salivary gland cancer stage IV

IndicationStatusPhase
DBCOND0028780 (Stage IV Salivary Gland Cancer)Terminated1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00906360Sunitinib, Cetuximab, and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Squamous Cell Carcinoma of the Head and NeckTreatment